

A Snapshot of What We Got Up To This Year...!



Support ♥ Awareness ♥ Research

CureDM is a small yet mighty collective of families, carers, loved ones and special individuals. We would like to thank everyone who makes CureDM charity what it is.

We've seen our donations almost double in 2022 / 23 and our expenditure has increased to reflect this. This simply wouldn't have been possible without your support! We would like to sincerely give thanks to those whose efforts, contributions, and donations - big and small- make up the CureDM community.

Thank You!

All the Trustees on our panel have the unique perspective of being parents and caregivers to a child / young adult diagnosed with Congenital Myotonic Dystrophy or a similar neuromuscular condition...



Emma-Jayne Ashley
Founding Director & Trustee
Mum to Dregan (CDM)



Peter Ashley
Trustee & Chair
Dad to Dregan (CDM)



Stephen Uncles
Trustee
Dad to Matthew & husband to Paula (CDM & DM1)



Dr. Ali Kay
Trustee
Mum to Bertie (Ullrich CMD)



In 2022 we gave a warm welcome to two new additions to the CureDM Trustees...



Tamsyn Tate
Trustee
Mum to Daisy (CDM & DM1)

"I am really excited to join the CureDM team. My two-year-old daughter's diagnosis of CDM1 and my own subsequent diagnosis of DM1 means I can relate to those who have the condition whilst caring for a child with the severe form. With a career as a Marketing Manager, I'm hoping I can help raise the charity's profile and ultimately awareness for the disease. I am also keen to support others through their journey."

"I'm delighted to be joining the CureDM team. My one-year-old son was diagnosed with CDM shortly after birth along with my wife (DM1). The news came as a huge shock, as it does for many families. I look forward to contributing to the charity's fantastic work in community support, as well as raising awareness within the science and medical community to move towards effective treatment."



Liam Garwood
Dad to Louie, husband to Bayley (CDM & DM1)

(Learn more about the team by visiting our web site)

Ongoing Support

This year, like every year, we make efforts to let children and their families, carers and guardians know we are thinking of them and follow their journeys as much as possible. We try to offer emotional support and informative advice whenever we can. Many of the CureDM community face daily challenges such as the shock of diagnosis, illness, and often being in hospital. We hope, through our network, we can help support one another and let you know you are not alone.

"CureDM has been a lifeline of hope and reassurance to us. Getting the shock diagnosis, we didn't know where to turn for information and found so little positive information out there. The charity has really helped our understanding and made us feel more hopeful for the future."

Events of 2022

Families Day - Alton Towers - July

We were able to organise an incredible family day to give families affected by CDM the opportunity to enjoy the theme park with minimal cost to them. This also gave families, carers, and guardians across the UK the opportunity to meet face-to-face and offer a safe space to connect with others familiar with the issues of caring for children affected by CDM. We received lots of lovely feedback about how much fun the attendees had and what a positive experience it was.



If you attended Alton Towers this year you may have seen a friendly, somewhat cuddly character in the form of Miles the Mascot. We hope you enjoyed this new addition to our team. Watch out for him at our future events!



"What a fantastic experience for our daughter to meet with so many other children who share her condition. She's only met two other children who have this condition..."

...I wish this charity had existed 11 years ago when we collected her from hospital...This charity is a wealth of knowledge on this condition and bringing us together is very special."



Disney On Ice - Sheffield, Birmingham, London - December

We were also able to offer a Winter family event this year. We secured spaces at three venues, offering 55 people the chance to enjoy a family trip to watch Disney on Ice live at Birmingham, Sheffield, or London with minimal personal cost to the families. It was lovely to be able to give the families another chance to meet up. For some it was the first time attending one of our events. We hope those who could make it made some unforgettable memories for the festive season! It was so successful that we are repeating the offer in 2023 - contact us if you are interested!



"[CureDM} has been a constant source of support and knowledge over the past year when the children have been ill, or I have had questions or concerns."

"We have really enjoyed and benefitted from the two meet ups (both Alton Towers in the Summer and Disney on Ice in December) where we got to meet many other families with children who have the same condition as my two..."



...That for me is the best part as it has allowed me to build a network of support of other mums / dads who may be going through similar...This gives me hope and reassurance, knowing I am not alone!



Research

At last, 3 potential systemic treatments are in clinical trials (AMO Pharma, Avidity and Dyne) and more are on the way!

CureDM are working with the companies to make sure the trials measure what is important to us, that they are not too much of a burden, and are safe. We are also working with the UK regulatory bodies to speed up the approval process and make them available to everyone as soon as possible. Please get in touch if you'd like to know more or to be involved!

MDUK announced in 2022 that Dr.Chris Turner at UCL will be leading a natural history study of adults with Congenital DM1 (symptoms from birth). The study will give us information to further improve care and also provide data for clinical trials.

Members of CureDM advocated for this study and we are proud to be part-funding it.

We have been involved in producing a number of abstracts and posters that have been presented at conferences by CureDM, TREAT-NMD, and the UK DM Patient Registry (which we also part-fund) to explain to clinicians and researchers the real-world experiences of the people that actually live with Myotonic Dystrophy.

Thank you for the hundreds of responses to our ongoing survey that allowed this to happen!

Congenital and Childhood Myotonic Dystrophy Type 1 in the UK
 Nikolenko Nikolaetta¹, Ashley Emma-Jayne²
¹National Hospital for Neurology and Neurosurgery, Queen Square, UCLH NHS Foundation Trust, UK
²Cure Myotonic Dystrophy UK Charity

Introduction

- Myotonic Dystrophy type 1 (DM1) is the most common form of adult onset muscular dystrophy, with some 200,000 people affected in the UK (1).
- DM1 is a progressive, autosomal dominant disorder, with no disease modifying treatment (2). Manifestations include distal muscle weakness, myotonia, arrhythmias, and other multisystemic manifestations.
- Congenital DM1 (CDM1) is the most severe subtype of DM1, characterised by signs and symptoms at birth or within the first months of life.
- Childhood DM1 presents with signs and symptoms between 1 month and 10 years of age. There is a marked disease severity in those with congenital and infantile subtypes.
- Congenital and pre-pubescent DM1 often causes cognitive difficulties such as learning disability, language associated with autism spectrum disorder and cognitive decline.
- Despite the low penetrance of DM1 in children, pre-pubescent DM1 has resulted in the identification of potential new targeted therapies for children, adolescents, and adults with congenital and childhood onset DM1.
- There is limited information around prevalence and epidemiology of paediatric onset DM1 in the UK, contributing to the disease progress and patient burden from childhood to adult onset and healthcare system.
- Identifying these needs, will ultimately improve healthcare services, long term outcomes and quality of life.

Aim

To identify the epidemiology and clinical characteristics of DM1 patients within the UK

Methods

- Cure DM1 is a registered charity, supporting patients and families living with Myotonic Dystrophy within the UK.
- Focus on raising awareness and improving quality of life, particularly for those living with congenital and childhood onset DM1.
- An initial, observational, online questionnaire was sent to DM1 patients and families in the UK via email, online and social media, and also via the UK Myotonic Dystrophy Patient Registry.
- Ongoing access to the questionnaire is available on the Cure DM website, with data being collected on an ongoing basis.
- The questionnaire was answered by the patients themselves or by their caregivers.

Results

Over 800 responses have been received to date, including 40 congenital and 120 childhood onset DM1. Other patients or caregivers completed the questionnaire, enabling a full inclusion for those with more severe disease subtypes.

Key gathered included sex, onset time, age at onset, and age of diagnosis. CTE reports were available. Healthcare services accessed and support of disease, and psychosocial burden were also reported.

Demographic data around disease onset to the patient shows a wide spread around the UK (Fig 1).

Notable differences were revealed between congenital and childhood DM1, in both specific disease symptoms and patient healthcare received.

	congenital	childhood	prevalence
Sex - female	12 (30.0%)	20 (16.7%)	100
Sex - male	28 (70.0%)	100 (83.3%)	100
Age at diagnosis	0.0 (0.0%)	0.0 (0.0%)	100
Onset			
Infant	30 (75.0%)	10 (8.3%)	100
Toddler	10 (25.0%)	90 (75.0%)	100
Childhood	0 (0.0%)	0 (0.0%)	100
Adolescence	0 (0.0%)	0 (0.0%)	100
Young adulthood	0 (0.0%)	0 (0.0%)	100
Adulthood	0 (0.0%)	0 (0.0%)	100
Older adulthood	0 (0.0%)	0 (0.0%)	100

Conclusion

Congenital and Childhood onset DM1 is complex and not widely understood, both within the patient population and their supporting care in the community.

Other than living with the most severe aspects of the disease no routine appropriate care and support.

Results from this survey can be used to facilitate the engagement in healthcare for patients with congenital and childhood onset DM1 in the UK.

References

(1) Johnson M, Barohn R, Brown K, Rowland C, Mankin C, Davis S, David S, Hildebrand M, Gorman M. Myotonic Dystrophy: Diagnosis and Management. *Genetics Home Reference*. National Center for Human Genome Research. Washington, DC: US Department of Health and Human Services; 2015. (2) Harper PS, Williamson D, eds. *Myotonic Dystrophy*, 3rd edn. Harwood Academic Press; London, 2002.

Acknowledgements and Contact


We acknowledge the UK Myotonic Dystrophy Patient Registry for helping with the dissemination of the questionnaire. We thank Ashley Emma-Jayne for her assistance in the UK and gene partners to share their photographs. Thank you.

Presenting author contact details: Emma-Jayne Ashley E-mail:ashley@mduk.org.uk

University College London **MDS** **UCL**

Raising Awareness

Shining a light on Myotonic Dystrophy, especially the Congenital form, is crucial. Here are some of examples how we spread the word this year:



Celebrating International DM Awareness Day:

Social media came into its own, especially Facebook and Twitter, where many in the UK community and beyond showed support by changing their profile pictures, sharing information on the disease, upcoming trials, and posting personal stories. The national mourning of the Queen meant landmarks that were planned to light up green on the 15th of September were purple in respect for the monarchy. They have, however, all said they'll light up for us in 2023!

Growing Our Strong Online Presence:


As well as the CureDM web site, this year we added Instagram to our continuous, strong online presence on social media, helping us to share any news and breakthroughs. Our private, UK only, Facebook group continued to grow. It is only for those living with DM, focusing on peer support and day to day living.



www.curedm.co.uk

Attending Conferences:

This year we got back to face-to-face conferences in the UK, Belgium, Italy and Canada and also presented at the prestigious IDMC. These allowed us to connect with the leading medical and scientific professionals, raising the profile of DM on a big stage.



Taking Part in Webinars:


In 2022/2023 we attended online conferences based in the UK, across Europe, Japan and the USA. As with in-person conferences, these webinars allow the exchange of medical advances in the field of neuromuscular disease and create collaborations that raise the profile and accelerate awareness of Myotonic Dystrophy.

Presenting the importance of patient preferences in webinars for ISPOR (Professional Society for Health Economics and Outcomes Research) and representing the community in online conferences is vital for keeping DM relevant in the eyes of the researchers.

Contacting Professionals:

We increased our efforts to make positive contact with medical professionals to bring recognition and further their understanding of the disease, to speed up diagnosis and implement the necessary care to their patients living with Myotonic Dystrophy earlier rather than later. Being members of Euro-DyMA (Federation of European DM Associations) and other DM specific associations enables us to bring meaningful discussion and collaboration to the very start of any project, making sure work is relevant for the community we represent.

This year we created a "Could it be Myotonic Dystrophy?" poster that has been distributed to clinicians and sent around the world. This can be downloaded from our website or please contact us for copies.



Raising Funds!

None of this would happen without the generous organisations that provide us with grants and, of course, the many amazing people that volunteer for us and selflessly raise the much needed money! You are fabulous!



For more information on CureDM and what we are doing behind the scenes, you can keep up to date on our social media pages, visit our website, or e-mail us at curedm@outlook.com

